Uncategorized

BioVie shares halve on murky Parkinson’s disease readout

BioVie shares halve on murky Parkinson’s disease readout

Published

on

BioVie’s stock fell by nearly 50% as the biotech claimed victory in a mid-stage Parkinson’s disease trial using an alternative endpoint to the one submitted to the FDA.​ ​Read More

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version